scholarly journals Integrating Open Data on Cancer in Support to Tumor Growth Analysis

2016 ◽  
pp. 49-66 ◽  
Author(s):  
Fleur Jeanquartier ◽  
Claire Jean-Quartier ◽  
Tobias Schreck ◽  
David Cemernek ◽  
Andreas Holzinger
Keyword(s):  
Tumor Growth ◽  
Growth Analysis ◽  
Open Data

scholarly journals TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Louie Semaan ◽  
Navneet Mander ◽  
Michael L. Cher ◽  
Sreenivasa R. Chinni
Keyword(s):  
Prostate Cancer ◽  
Tumor Growth ◽  
Bone Tumor ◽  
Bone Tumors ◽  
Growth Analysis ◽  
Biosynthetic Enzyme ◽  
Enzyme Expression ◽  
Oncogenic Signaling ◽  
Androgen Synthesis

Abstract Background Castrate Resistant Prostate Cancer (CRPC) is an advanced disease resistant to systemic traditional medical or surgical castration, and resistance is primarily attributed to reactivation of AR through multiple mechanisms. TMPRSS2-ERG fusions have been shown to regulate AR signaling, interfere with pro-differentiation functions, and mediate oncogenic signaling. We have recently shown that ERG regulates intra-tumoral androgen synthesis and thereby facilitates AR function in prostate cancer cells. We hypothesize that enzalutamide treatment will be more effective in cells/tumors with TMPRSS2-ERG translocations because these tumors have increased AR signaling. Methods ERG knockdown was performed with VCaP cells using lentiviral infections to generate VCaP ERGshRNA cells and control VCaP scr cells with scrambled shRNA. Cell-growth analysis was performed to determine the effect of enzalutamide. Reverse transcription, quantitative real-time PCR (RT-qPCR) was used to determine the expression of AR responsive genes. Luciferase tagged VCaP scr and shRNA infected cells were used in an intra-tibial animal model for bone tumor growth analysis and enzalutamide treatment used to inhibit AR signaling in bone tumors. Western blotting analyzed VCaP bone tumor samples for ERG, AR, AKR1C3 and HSD3B1 and HSD3B2 expression. Results Enzalutamide inhibited the growth of VCaP scr cells more effectively than shERG cells. Analysis of AR responsive genes shows that Enzalutamide treatment at 5 micromolar concentration inhibited by 85–90% in VCaP Scr cells whereas these genes were inhibited to a lesser extent in VCaP shERG cells. Enzalutamide treatment resulted in severe growth inhibition in VCaP scr shRNA cells compared to VCaP shERG cells. In bone tumor growth experiment, VCaP ERG shRNA cells grew at slower than VCaP scr shRNA cells. Androgen biosynthetic enzyme expression is lower VCaP shERG bone tumors compared to VCaP scr shRNA bone tumors and enzalutamide inhibited the enzyme expression in both types of tumors. Conclusions These data suggest that ERG transcription factor regulates androgen biosynthetic enzyme expression that enzalutamide treatment is more effective against VCaP bone tumors with an intact ERG expression, and that knocking down ERG in VCaP cells leads to a lesser response to enzalutamide therapy. Thus, ERG expression status in tumors could help stratify patients for enzalutamide therapy.

A new model for tumor growth analysis based on a postulated inhibitory substance

1980 ◽  
Vol 13 (5) ◽  
pp. 437-445 ◽  
Author(s):  
Edwin B. Cox ◽  
Max A. Woodbury ◽  
Lawrence E. Myers
Keyword(s):  
Tumor Growth ◽  
Growth Analysis ◽  
Inhibitory Substance ◽  
New Model

Tectal Lesions in Children: A Long-Term Follow-Up Volumetric Tumor Growth Analysis in Surgical and Nonsurgical Cases

2016 ◽  
Vol 51 (2) ◽  
pp. 69-78 ◽  
Author(s):  
Amir Kershenovich ◽  
Zmira Silman ◽  
David de Rungs ◽  
Korgun Koral ◽  
Lynn Gargan ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Growth Analysis ◽  
Long Term Follow Up

655: EBAG9/RCAS1 Expression Enhances Tumor Growth in Renal Cell Carcinoma

2005 ◽  
Vol 173 (4S) ◽  
pp. 178-179
Author(s):  
Tetsuo Ogushi ◽  
Takahashi Satoru ◽  
Takumi Takeuchi ◽  
Tetsuya Fujimura ◽  
Tomohiko Urano ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Growth ◽  
Cell Carcinoma ◽  
Renal Cell

815: Human Kallikrein 2 (HK2) Inhibitors Suppress Tumor Growth of Prostate Cancer Xenografts in Nude Mice

2006 ◽  
Vol 175 (4S) ◽  
pp. 263-263
Author(s):  
Christoph Kündig ◽  
Sylvain M. Cloutier ◽  
Steve Aellen ◽  
Loyse M. Felber ◽  
Jair R. Chagas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Growth ◽  
Nude Mice ◽  
Human Kallikrein 2 ◽  
Kallikrein 2

442: Stromal Hedgehog Pathway Activity Accelerates Prostate Tumor Growth

2006 ◽  
Vol 175 (4S) ◽  
pp. 143-143
Author(s):  
Aubie Shaw ◽  
Jerry Gipp ◽  
Wade Bushman
Keyword(s):  
Tumor Growth ◽  
Prostate Tumor ◽  
Hedgehog Pathway ◽  
Pathway Activity
Sign in / Sign up

Export Citation Format

Share Document